A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries
Open Access
- 11 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11
Abstract
Approximately 10% of global health research is devoted to 90% of global disease burden (the so-called “10/90 Gap”) and it often neglects those diseases most prevalent in low-income countries. Antibiotic resistant bacterial infections are known to impact on healthcare, food security, and socio-economic fabric in the developing countries. With a global antibiotic resistance crisis currently reaching a critical level, the unmet needs in the developing countries are even more striking. The failure of traditional antimicrobials has led to renewed interest in century-old bacteriophage (phage) therapy in response to the urgent need to develop alternative therapies to treat infections. Phage therapy may have particular value in developing countries where relevant phages can be sourced and processed locally and efficiently, breaking specifically the economic barrier of access to expensive medicine. Hence this makes phage therapy an attractive and feasible option. In this review, we draw our respective clinical experience as well as phage therapy research and clinical trial, and discuss the ways in which phage therapy might reduce the burden of some of the most important bacterial infections in developing countries.Keywords
This publication has 138 references indexed in Scilit:
- Gastrointestinal and Extra-Intestinal Manifestations of Childhood Shigellosis in a Region Where All Four Species of Shigella Are EndemicPLOS ONE, 2013
- Bacteriophages for managingShigellain various clinical and non-clinical settingsBacteriophage, 2013
- Bacteriophages and Their Role in Food SafetyInternational Journal of Microbiology, 2012
- The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal DiseaseClinical and Vaccine Immunology, 2012
- Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009International Journal of Antimicrobial Agents, 2012
- Phage treatment of human infectionsBacteriophage, 2011
- Antimicrobial Susceptibility and Mechanisms of Resistance in Shigella and Salmonella Isolates from Children under Five Years of Age with Diarrhea in Rural MozambiqueAntimicrobial Agents and Chemotherapy, 2009
- Drivers of tuberculosis epidemics: The role of risk factors and social determinantsSocial Science & Medicine, 2009
- Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in MiceAntimicrobial Agents and Chemotherapy, 2007
- The Control of Experimental Escherichia coli Diarrhoea in Calves by Means of BacteriophagesMicrobiology, 1987